Open Payments

The Moses H. Cone Memorial Hospital

Type
Teaching hospital
Where
Greensboro, NC
Medicare CCN
340091
Received
$1,621,375 in 364 records, 2019 ($124,745 general, $1,496,629 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment116$124,745
2019Research payment248$1,496,629

By company

CompanyRecordsAmountYears
CSL Behring35$321,7562019
PENTAX of America, Inc.1$209,1072019
Varian Medical Systems, Inc.2$186,2442019
CVRx, Inc.13$158,7722019
Amgen Inc.14$134,6342019
Medtronic Vascular, Inc.11$104,8242019
Merck Sharp & Dohme LLC23$92,8242019
SANOFI PASTEUR INC.2$88,8952019
PFIZER INC.71$65,3302019
Novartis Pharmaceuticals Corporation12$54,3602019
Abbott Laboratories12$34,7122019
Gilead Sciences, Inc.20$30,3612019
KARL STORZ Endoscopy-America26$26,4602019
Surmodics, Inc.17$25,4562019
Regeneron Pharmaceuticals, Inc.5$8,1862019
W. L. Gore & Associates, Inc.1$6,7502019
BIOTRONIK INC.26$6,3232019
Boston Scientific Corporation2$5,5002019
Zimmer Biomet Holdings, Inc.2$4,1722019
AstraZeneca Pharmaceuticals LP3$4,0002019
Genentech, Inc.4$3,8422019
Avanir Pharmaceuticals, Inc.2$3,7502019
E.R. Squibb & Sons, L.L.C.6$3,5972019
MERZ NORTH AMERICA, INC.1$3,0002019
Lundbeck LLC1$3,0002019
MDD US Operations, LLC2$3,0002019
Aesculap, Inc.1$2,7142019
Boehringer Ingelheim Pharmaceuticals, Inc.1$2,5002019
PORTOLA PHARMACEUTICALS, LLC3$2,5002019
ACELL, INC.2$2,4582019
Takeda Pharmaceuticals U.S.A., Inc.2$2,3002019
Covidien LP2$1,5002019
Linvatec Corporation1$1,4032019
Tandem Diabetes Care, Inc.5$1,4002019
ARRAY BIOPHARMA INC2$1,3002019
KYOWA KIRIN, INC.2$1,3002019
Becton, Dickinson and Company1$1,2002019
GENZYME CORPORATION2$1,0502019
KCI USA, Inc.1$1,0002019
Endo Pharmaceuticals Inc.1$1,0002019
Genentech USA, Inc.1$1,0002019
Penumbra, Inc.1$7502019
Optinose US, Inc.1$7502019
ABBVIE INC.2$6502019
Amarin Pharma, Inc.1$6502019
Medline Industries LP2$6002019
TAIHO ONCOLOGY, INC.2$6002019
ConvaTec Inc.2$6002019
MOLNLYCKE HEALTH CARE US, LLC1$4002019
Smith+Nephew, Inc.1$4002019

By nature of payment

NatureRecordsAmount
Research payment248$1,496,629
Space rental or facility fees (teaching hospital only)63$50,612
Gift29$33,346
Grant5$26,903
Education6$5,508
Compensation for services other than consulting, including serving as faculty or as a speaker at a v11$5,043
Charitable Contribution2$3,331

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31CVRx, Inc.$5,160Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2019
2019-12-31Zimmer Biomet Holdings, Inc.$3,547GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31CVRx, Inc.$3,100Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2019
2019-12-31Linvatec Corporation$1,403GrantIn-kind items and services2DHD MONITORS Device, ORTHOPEDIC SURGERY2019
2019-12-31Zimmer Biomet Holdings, Inc.$625GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31Siemens Medical Solutions USA, Inc.$331Charitable ContributionIn-kind items and services2019
2019-12-27PFIZER INC.$1,800Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-12-25Amgen Inc.$1,575Research paymentCash or cash equivalentRepatha Biological, CardiologyGOULD2019
2019-12-25Amgen Inc.$1,043Research paymentCash or cash equivalentGALACTIC-HF2019
2019-12-25CVRx, Inc.$5Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2019
2019-12-24KARL STORZ Endoscopy-America$1,020GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-12-24KARL STORZ Endoscopy-America$1,020GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$1,590GiftIn-kind items and servicesNEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$1,470GiftIn-kind items and servicesNEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$1,290GiftIn-kind items and servicesNEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$1,020GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$1,020GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$990GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-12-19KARL STORZ Endoscopy-America$720GiftIn-kind items and servicesINSERT,BOWEL GRASPER,FENESTRAT Device, LAPAROSCOPY2019
2019-12-19Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-19Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-18CVRx, Inc.$30,000Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2019
2019-12-18Gilead Sciences, Inc.$1,450Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-12-18Gilead Sciences, Inc.$1,358Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2019
2019-12-17Merck Sharp & Dohme LLC$4,223Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-12-16Becton, Dickinson and Company$1,200Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-12-16Medtronic Vascular, Inc.$667Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-12-12CSL Behring$9,468Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-12-11Abbott Laboratories$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentMitra Clip system Device, Vascular2019
2019-12-06PFIZER INC.$7,500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-12-05CSL Behring$7,991Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-12-05CSL Behring$850Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-28Amgen Inc.$2,504Research paymentCash or cash equivalentRepatha Biological, CardiologyVESALIUS-CV2019
2019-11-20CVRx, Inc.$30,000Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2019
2019-11-20Gilead Sciences, Inc.$691Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-11-20Gilead Sciences, Inc.$491Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2019
2019-11-14Medtronic Vascular, Inc.$2,959Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-11-14KYOWA KIRIN, INC.$1,000EducationCash or cash equivalentPOTELIGEO Drug, MONOCLONAL ANTIBODY2019
2019-11-13Abbott Laboratories$6,796Research paymentCash or cash equivalentAMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart FailureAMPLATZER PFO Occluder Post Approval Study2019
2019-11-13Regeneron Pharmaceuticals, Inc.$600Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Pa2019
2019-11-12Boston Scientific Corporation$2,500GrantCash or cash equivalentGENERAL - VASCULAR INTERVENTION Device, VASCULAR2019
2019-11-08Merck Sharp & Dohme LLC$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentKEYTRUDA Biological, ONCOLOGY2019
2019-11-08PORTOLA PHARMACEUTICALS, LLC$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentANDEXXA Biological, HEMATOLOGY/NEUROLOGY2019
2019-11-07CSL Behring$23,447Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-07CSL Behring$1,050Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-06Regeneron Pharmaceuticals, Inc.$943Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMLong Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hype2019
2019-10-31PFIZER INC.$1,800Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-10-30Abbott Laboratories$2,232Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-10-28CVRx, Inc.$18,395Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2019
2019-10-25Varian Medical Systems, Inc.$131,266Research paymentCash or cash equivalentAuto-Segmentation - Cone Health2019
2019-10-25Varian Medical Systems, Inc.$54,978Research paymentCash or cash equivalentAuto-Segmentation - Cone Health2019
2019-10-25ConvaTec Inc.$200Space rental or facility fees (teaching hospital only)Cash or cash equivalentFLEXI-SEAL FMS Device, CONTINENCE AND CRITICAL CARE2019
2019-10-23Gilead Sciences, Inc.$1,182Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-10-23Gilead Sciences, Inc.$679Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2019
2019-10-22PENTAX of America, Inc.$209,107Research paymentIn-kind items and services Device, GastroenterologyFDA post market Sampling and Culturing Study (FDA 522- PS15004/PS002)2019
2019-10-16Abbott Laboratories$1,100Research paymentCash or cash equivalentXience Device, Cardiac Arrhythmias and Heart FailureXIENCE SHORT DAPT 28 US2019
2019-10-14Medtronic Vascular, Inc.$3,445Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-10-10CSL Behring$19,660Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-10CSL Behring$850Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-09Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-02Amgen Inc.$34,622Research paymentIn-kind items and servicesRepatha Biological, CardiologyVESALIUS-CV2019
2019-10-02Regeneron Pharmaceuticals, Inc.$2,278Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMLong Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hype2019
2019-09-30PFIZER INC.$3,600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-09-26Medline Industries LP$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-09-19Merck Sharp & Dohme LLC$5,000Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-09-19Merck Sharp & Dohme LLC$2,875Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-09-19Boehringer Ingelheim Pharmaceuticals, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-09-19Merck Sharp & Dohme LLC$2,000Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-09-19Merck Sharp & Dohme LLC$1,400Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-09-19Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-09-18Gilead Sciences, Inc.$2,364Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-09-18Gilead Sciences, Inc.$1,170Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2019
2019-09-17SANOFI PASTEUR INC.$49,680Research paymentCash or cash equivalentYELLOW FEVER DrugSTA00011 Stamaril Yellow Fever2019
2019-09-17CSL Behring$49,611Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-09-17CSL Behring$2,400Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-09-12AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentBRILINTA Drug, Cardiovascular and Metabolism2019
2019-09-09Medtronic Vascular, Inc.$17,978Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-09-09CSL Behring$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-08-29Merck Sharp & Dohme LLC$7,997Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-08-27CVRx, Inc.$4,192Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2019
2019-08-26PFIZER INC.$3,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-08-21Gilead Sciences, Inc.$1,188Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-08-21Regeneron Pharmaceuticals, Inc.$1,125Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Pa2019
2019-08-21KCI USA, Inc.$1,000EducationCash or cash equivalentVAC VERAFLO Device, DEVICES2019
2019-08-13CSL Behring$22,400Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-13CSL Behring$800Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-08Medtronic Vascular, Inc.$168Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-08-07Takeda Pharmaceuticals U.S.A., Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentNINLARO Drug, Oncology2019
2019-08-06Genentech, Inc.$968Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2019
2019-08-06Merck Sharp & Dohme LLC$850Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-07-31Abbott Laboratories$1,749Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-07-30PFIZER INC.$3,550Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-07-24Abbott Laboratories$3,581Research paymentCash or cash equivalentAMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart FailureAMPLATZER PFO Occluder Post Approval Study2019
2019-07-23Merck Sharp & Dohme LLC$1,924Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-07-17Gilead Sciences, Inc.$1,679Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-07-17Surmodics, Inc.$849Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-07-12Lundbeck LLC$3,000Charitable ContributionCash or cash equivalentNORTHERA Drug, NEUROLOGY2019
2019-07-12Optinose US, Inc.$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentXhance Drug, Otolaryngology (Ear, Nose, Throat)2019
2019-07-12Novartis Pharmaceuticals Corporation$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentXOLAIR Biological, RESPIRATORY2019
2019-07-12GENZYME CORPORATION$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentDUPIXENT Drug, IMMUNOLOGY2019
2019-07-12Covidien LP$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentAuto Suture Device, Surgical Stapling2019
2019-07-11CSL Behring$14,813Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-07-11CSL Behring$700Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-07-10Novartis Pharmaceuticals Corporation$38,666Research paymentCash or cash equivalentKISQALI Drug, ONCOLOGYRIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE2019
2019-07-08Amgen Inc.$2,195Research paymentIn-kind items and servicesRepatha Biological, CardiologyVESALIUS-CV2019
2019-07-07KARL STORZ Endoscopy-America$1,590GiftIn-kind items and servicesTROCAR,ONLY,BLUNT,11MM,10.5CM, Device, LAPAROSCOPY2019
2019-07-07KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-07KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-07KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-06KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-06KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-06KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-06KARL STORZ Endoscopy-America$900GiftIn-kind items and servicesOUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY2019
2019-07-03CVRx, Inc.$29Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2019
2019-06-26Merck Sharp & Dohme LLC$4,800Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-06-26ConvaTec Inc.$400Space rental or facility fees (teaching hospital only)Cash or cash equivalentAQUACEL AG Device, WOUND THERAPEUTICS2019
2019-06-25Endo Pharmaceuticals Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentNASCOBAL Drug, PRESCRIPTION SUPPLEMENT2019
2019-06-21ABBVIE INC.$350Space rental or facility fees (teaching hospital only)Cash or cash equivalentOrilissa Drug, Endocrinology2019
2019-06-19Gilead Sciences, Inc.$3,116Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-06-19Gilead Sciences, Inc.$1,154Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2019
2019-06-19PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-19PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-06-11CSL Behring$21,537Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-06-11CSL Behring$900Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-06-09AstraZeneca Pharmaceuticals LP$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentSYMBICORT Drug, Respiratory2019
2019-06-09AstraZeneca Pharmaceuticals LP$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentFASENRA Drug, Respiratory2019
2019-06-06Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-06-05Medtronic Vascular, Inc.$115Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-05-30CSL Behring$1,200Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-05-29ACELL, INC.$1,229EducationCash or cash equivalent2019
2019-05-29ACELL, INC.$1,229EducationCash or cash equivalent2019
2019-05-23Surmodics, Inc.$1,266Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-05-23Surmodics, Inc.$979Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-05-23Surmodics, Inc.$594Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-05-22Regeneron Pharmaceuticals, Inc.$3,239Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Pa2019
2019-05-22Gilead Sciences, Inc.$740Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-05-22CVRx, Inc.$23Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2019
2019-05-21E.R. Squibb & Sons, L.L.C.$90Research paymentCash or cash equivalentOPDIVO Biological, OncologyA Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemothera2019
2019-05-20PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-20PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-17W. L. Gore & Associates, Inc.$6,750Research paymentCash or cash equivalentProduct in Development Device, DevicesGORE EXCLUDER Conformable Endoprosthesis2019
2019-05-17E.R. Squibb & Sons, L.L.C.$1,000Research paymentCash or cash equivalentOPDIVO Biological, OncologyA Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer W2019
2019-05-16Merck Sharp & Dohme LLC$2,500Research paymentCash or cash equivalentMK-0859 Drug, CARDIOVASCULARHPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran2019
2019-05-15Abbott Laboratories$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentMitra Clip system Device, Vascular2019
2019-05-14Medtronic Vascular, Inc.$18,277Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-05-14BIOTRONIK INC.$212Research paymentCash or cash equivalentSiello Device, Cardiology/Vascular DiseasesSIELLO2019
2019-05-14BIOTRONIK INC.$175Research paymentCash or cash equivalentSiello Device, Cardiology/Vascular DiseasesSIELLO2019
2019-05-09CSL Behring$41,012Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-05-09CSL Behring$1,800Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-05-06Aesculap, Inc.$2,714GiftCash or cash equivalent2019
2019-05-02Novartis Pharmaceuticals Corporation$1,000Research paymentCash or cash equivalentTYKERB Drug, ONCOLOGYA PHASE I DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LAPATINIB IN COMBINATION WITH CARBOPLATIN PACLI2019
2019-05-02Surmodics, Inc.$849Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-05-02Surmodics, Inc.$849Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-05-02PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-02PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-02PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-02PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-02PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-02PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-02Surmodics, Inc.$594Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-05-02PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-05-01Abbott Laboratories$2,214Research paymentCash or cash equivalentAMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart FailureAMPLATZER PFO Occluder Post Approval Study2019
2019-05-01Medline Industries LP$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-04-30Covidien LP$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentBIS Device, Cerebral/Somatic Oximetry2019
2019-04-29Novartis Pharmaceuticals Corporation$2,630Research paymentCash or cash equivalentAFINITOR Drug, ONCOLOGYAN OPEN LABEL PHASE II SINGLE ARM STUDY OF EVEROLIMUS IN COMBINATION WITH LETROZOLE IN THE TREATMENT OF POSTMENOPAUSAL W2019
2019-04-26Penumbra, Inc.$750EducationCash or cash equivalent2019
2019-04-26Genentech, Inc.$484Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2019
2019-04-25Medtronic Vascular, Inc.$35Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2019
2019-04-24CVRx, Inc.$16,113Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2019
2019-04-24Abbott Laboratories$4,781Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-04-24Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-04-23PORTOLA PHARMACEUTICALS, LLC$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentANDEXXA Biological, HEMATOLOGY/NEUROLOGY2019
2019-04-18Smith+Nephew, Inc.$400Space rental or facility fees (teaching hospital only)Cash or cash equivalentREDAPT Revision Hip System Device, Recon Hips2019
2019-04-18Astellas Pharma US Inc$300Space rental or facility fees (teaching hospital only)Cash or cash equivalentXTANDI Drug, ONCOLOGY2019
2019-04-17Medtronic Vascular, Inc.$1,875Research paymentCash or cash equivalentCareLink Device, Cardiac Diagnostics and MonitoringBlueSync2019
2019-04-17Gilead Sciences, Inc.$1,730Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2019
2019-04-17Gilead Sciences, Inc.$1,181Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2019
2019-04-17Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-04-17PFIZER INC.$300Space rental or facility fees (teaching hospital only)Cash or cash equivalentSUTENT Drug, ONCOLOGY;RESPIRATORY2019
2019-04-16CSL Behring$11,279Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-04-16PFIZER INC.$1,750Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-04-16PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019
2019-04-16PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2019

The latest 200 records of 364.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Guilford CountyGreensboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.

MeasurePlace (city or town)
Greensboro, NC
County
Guilford County, NC
State
North Carolina
Population B01003301,198547,94010,730,404
Population, 2020 census P1299,035541,29910,439,388
Median age B0100234.337.539.1
Under 18 B0100121.7%22.0%21.8%
65 and over B0100114.4%15.9%17.2%
Households B11001123,984219,7184,282,345
Foreign born B0500212.7%11.8%9.1%
Median household income B19013$61,515$68,642$72,388
Median family income B19113$80,585$88,156$90,290
Per capita income B19301$37,531$39,376$41,385
Poverty rate B1700117.0%14.6%13.0%
Unemployment rate B230255.1%4.6%4.7%
Civilian labor force B23025158,568282,3625,336,863
Mean commute (minutes) B0801321.722.025.1
Bachelor's degree or higher B1500341.0%39.0%35.7%
Housing units B25001135,665238,0324,895,668
Owner-occupied B2500350.5%59.9%66.6%
Renters B2500349.5%40.1%33.4%
Median home value B25077$244,800$259,900$288,900
Median gross rent B25064$1,172$1,163$1,228
White, not Hispanic B0300238.1%46.0%60.0%
Black B0300241.0%33.5%20.0%
Hispanic or Latino B0300210.5%10.1%11.3%
Asian B030025.2%5.4%3.3%
American Indian and Alaska Native B030020.2%0.1%0.8%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.